Silence Therapeutics PLC（SLN）のニュースとイベントSLNSilence Therapeutics PLC

Significant Increases in Borrow Rates for Liquid Options

Latest data shows the largest indicative borrow rate increases among liquid option names include: iShares Global Clean Energy (ICLN) 20.40% +7.74, Live Microsystems (LVWR) 391.27% +5.91, Faraday Future Intelligent Electric Inc (FFAI) 315.21% +1.06, SILENCE THERAPEUTICS PLC SPONSORED ADR (SLN) 1.05% +0.63, Ericsson (ERIC) 3.49% +0.62, Tradr 2X Short SNDK Daily ETF (SNDQ) 39.77% +0.44, Western Union (WU) 1.34% +0.40, Defiance Daily Target 2X Long RKLB ETF (RKLX) 13.91% +0.35, Tradr 2X Long CRWV Daily ETF (CWVX) 7.01% +0.34, and NovaDel Pharma (NVDL) 12.49% +0.30.

Jefferies, Morgan Stanley, and Others Jointly Manage Proposed Offering

Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book-running managers for the proposed offering.

Silence Therapeutics Reports Positive Phase 2 Results for Divesiran

Silence Therapeutics announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera. The 36-week, randomized, double-blind, placebo-controlled portion of the Phase 2 trial evaluating divesiran administered subcutaneously every six weeks or every twelve weeks met its primary endpoint and secondary endpoints. Key findings from the study include: The primary endpoint was met, with a significantly higher proportion of clinical responders among divesiran-treated patients with PV compared to those who received placebo. The primary endpoint was the proportion of patients achieving a response, which was defined as the absence of phlebotomy and maintenance of hematocrit below 45% during weeks 18-36. Both divesiran dose groups showed substantial primary endpoint efficacy with response rates of 93.8% and 81.3% for Q6W and Q12W, respectively. The key secondary endpoint of phlebotomy rate during weeks 0-36 was also met with the mean number of phlebotomies per patient in the divesiran groups significantly reduced compared to placebo.